Your health feed.
Personalized to what matters.

Tirzepatide and Lean Mass Preservation: 72-Week Follow-Up Data

Extended follow-up from the SURMOUNT trials shows lean mass loss averages 38% of total weight lost on tirzepatide — reinforcing the clinical need for resistance training and leucine supplementation protocols during GLP-1 therapy.

Ferrous Bisglycinate vs. Ferrous Sulfate: Head-to-Head Tolerability RCT

Multicenter randomized controlled trial confirms ferrous bisglycinate achieves equivalent iron repletion with significantly fewer GI adverse events vs. ferrous sulfate in non-pregnant adults with iron deficiency anemia.

Ashwagandha KSM-66: What the Evidence Actually Shows in 2025

Updated summary of 24 randomized controlled trials confirms statistically significant cortisol reduction, testosterone increase in deficient men, and VO2 max improvement. Optimal dose confirmed at 600 mg/day.

Resistance Training for GLP-1 Patients: New ACSM Position Statement

ACSM releases guidance specifically for GLP-1 agonist patients: 3× per week resistance training combined with 2.5–3g/day leucine preserves lean mass during rapid weight loss, reducing sarcopenia risk by up to 60%.

Lion's Mane Mushroom and Nerve Growth Factor: Updated Clinical Evidence

Systematic review of 8 RCTs confirms Hericium erinaceus at 1–2g/day significantly improves subjective cognitive function scores and promotes NGF synthesis in adults with mild cognitive impairment.

NMN Supplementation in Older Adults: Phase II Trial Results

Placebo-controlled trial in adults aged 65–80 shows 500 mg/day NMN for 12 weeks significantly increases NAD+ bioavailability and improves muscle strength and gait speed vs. placebo. Dose-response analysis included.

Perimenopause and Sleep Disruption: Evidence-Based Non-Hormonal Interventions

Annals of Internal Medicine reviews CBT-I, phytotherapy including black cohosh and sage leaf, and magnesium supplementation as first-line non-hormonal options for sleep-related menopausal symptoms. Sage leaf shows 50% hot flash reduction.

Berberine for Pre-Diabetes: Systematic Review and Meta-Analysis of 14 RCTs

Meta-analysis confirms berberine 1000–1500 mg/day reduces fasting glucose and HbA1c comparably to metformin 500 mg twice daily in patients with impaired fasting glucose. Ceylon cinnamon co-administration shows additive effect.

Iron Supplementation: Updated Dosing Guidelines and Drug Interactions

Updated NIH Office of Dietary Supplements fact sheet clarifies therapeutic iron dosing ranges, absorption-inhibiting drug interactions with PPIs and tetracyclines, and updated tolerable upper intake levels.

The Gut-Brain Axis: How Your Microbiome Affects Mood and Sleep

Mayo Clinic Health Letter explores the bidirectional relationship between gut microbiome composition and mental health — including how L-glutamine, butyrate-producing bacteria, and prebiotic fiber influence anxiety and sleep quality.

L-Citrulline and Erectile Function: Network Meta-Analysis of 11 Trials

Meta-analysis confirms L-citrulline ≥3g/day significantly improves IIEF scores in men with mild-moderate ED. Pycnogenol co-administration shows synergistic eNOS upregulation effect with favorable safety profile.

Glycine Before Bed: RCT Evidence for Sleep Quality Improvement

Randomized controlled trial confirms glycine 3g taken 1 hour before bed significantly improves subjective sleep quality scores, reduces sleep onset latency, and improves next-day cognitive performance vs. placebo.

Zone 2 Training and Mitochondrial Health: Updated 2025 Guidelines

ACSM updates recommendations on low-intensity steady-state training, confirming 150–180 min/week of Zone 2 cardio significantly improves mitochondrial biogenesis, metabolic flexibility, and cardiovascular markers.

Vitamin D and Testosterone in Men: NIH Evidence Summary

NIH reviews 12 intervention trials confirming significant correlation between vitamin D sufficiency (>40 ng/mL) and total and free testosterone levels, particularly in men with baseline deficiency.

Fisetin as a Senolytic: First Human Dose-Escalation Study

First human dose-escalation study of fisetin demonstrates senescent cell clearance at 100–200 mg/day with favorable safety profile over 12 weeks. Researchers note synergistic effects with quercetin in combination protocols.